Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles

Therapeutic Delivery

Volumn 3, Issue 9, 2012, Pages 1077-1099

  McCullough, Kenneth C ^a   Bassi, Isabelle ^a   Démoulins, Thomas ^a   Thomann Harwood, Lisa J ^a   Ruggli, Nicolas ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ATELOCOLLAGEN; CHOLESTEROL; CYCLODEXTRIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOUBLE STRANDED RNA; LIPOPLEX; LIPOSOME; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; POLYETHYLENEIMINE; POLYLYSINE; POLYMETHACRYLIC ACID; PROTAMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTATION; CELL FUNCTION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMORAL IMMUNITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; IMMUNOSTIMULATION; INTERNALIZATION; MEMBRANE VESICLE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA REPLICATION; TARGET CELL;

EID: 84865713580     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.90     Document Type: Review

References (122)

1. McCullough KC, Summerfield A. Targeting the porcine immune system - particulate vaccines in the 21st century. Dev. Comp. Immunol. 33, 394-409 (2009).
2. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 13, 45-51 (2001). (Pubitemid 32096959)
3. Randolph GJ, Jacubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr. Opin. Immunol. 20, 52-60 (2008).
4. Jensen PE. Recent advances in antigen processing and presentation. Nat. Immunol. 8, 1041-1048 (2007). (Pubitemid 47423752)
5. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 27, 1-5 (2008).
6. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8, 607-618 (2008).
7. Collnot E-M, Ali H, Lehr C-M. Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Release 161, 235-246 (2012).
8. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161, 505-522 (2012).
9. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug. Del. Rev. 63, 943-955 (2011).
10. Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 6, 523-529 (2010).
11. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863 (2006). (Pubitemid 43261457)
12. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med. 41, 61-66 (2009).
13. Unger WW, van Beelen AJ, Bruijns SC et al. Glycan-modified liposomes boost CD4 (+) and CD8 (+) T-cell responses by targeting DC-SIGN on dendritic cells. J. Control. Release 160, 88-95 (2012).
14. Kumari S, Mg S, Mayor S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res. 20, 256-275 (2010).
15. Sandvig K, Pust S, Skotland T, van Deurs B. Clathrin-independent endocytosis: mechanisms and function. Curr. Opin. Cell Biol. 23, 413-420 (2011).
16. Platta HW, Stenmark H. Endocytosis and signaling. Curr. Opin. Cell Biol. 23, 393-403 (2011).
17. van Niel G, Wubbolts R, Stoorvogel W. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr. Opin. Cell Biol. 20, 437-444 (2008).
18. Norbury CC, Sigal LJ. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol. 15, 82-88 (2003). (Pubitemid 35454197)
19. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat. Rev. Immunol. 10, 403-414 (2010).
20. Heath W, Belz G, Behrens G M N et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9-26 (2004). (Pubitemid 38736761)
21. Monu N, Trombetta ES. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentationby MHC class I molecules. Curr. Opin. Immunol. 19, 66-72 (2007). (Pubitemid 46073703)
22. Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen. Curr. Opin. Immunol. 20, 89-95 (2008).
23. Bevan MJ. Cross-priming. Nat. Immunol. 7, 363-365 (2006).
24. Blankenstein T, Schuler T. Cross-priming versus cross-tolerance: are two signals enough? Trends Immunol. 23, 171-173 (2002). (Pubitemid 34260926)
25. Melief CJ. Mini-review: regulation of cytotoxic T-lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33, 2645-2654 (2003). (Pubitemid 37337130)
26. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8 (+) and CD8 (-) dendritic cells in vivo. J. Exp. Med. 196, 817-827 (2002).
27. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity. 19, 5-8 (2003). (Pubitemid 36859896)
28. Lutz MB, Kurts C. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur. J. Immunol. 39, 2325-2330 (2009).
29. Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr. Opin. Allergy Clin. Immunol. 9, 554-557 (2009).
30. Rescigno M. Dendritic cells in oral tolerance in the gut. Cell. Microbiol. 13, 1312-1318 (2011).
31. Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J. Clin. Invest. 119, 2441-2450 (2009).
32. Rescigno M, Lopatin U, Chieppa M. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. Curr. Opin. Immunol. 20, 669-675 (2008).
33. Rescigno M, Matteoli G. Lamina propria dendritic cells: for whom the bell TOLLs? Eur. J. Immunol. 38, 1483-1486 (2008).
34. Sabatte J, Maggini J, Nahmod K et al. Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. Cytokine Growth Factor Rev. 18, 5-17 (2007). (Pubitemid 46420546)
35. Chung Y, Chang JH, Kweon MN, Rennert PD, Kang CY. CD8a-11b+ dendritic cells but not CD8a+ dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 106, 201-206 (2005). (Pubitemid 40967193)
36. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol. 22, 109-117 (2010).
37. Belizaire R, Unanue ER. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl Acad. Sci. USA 106, 17463-17468 (2009).
38. Markov OO, Mironova NL, Maslov MA et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J. Control. Release 160, 200-210 (2012).
39. Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev. 57, 377-390 (2005). (Pubitemid 39550966)
40. Ji W, Panus D, Palumbo RN, Tang R, Wang C. Poly (2-aminoethyl methacrylate) with well-defined chain length for DNA vaccine delivery to dendritic cells. Biomacromolecules 12, 4373-4385 (2011).
41. Sun X, Chen S, Han J, Zhang Z. Mannosylated biodegradable polyethyleneimine for targeted DNA delivery to dendritic cells. Int. J. Nanomed. 7, 2929-2942 (2012).
42. Melhem NM, Gleason SM, Liu XD, Barratt-Boyes SM. High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA. Clin. Vaccine Immunol. 15, 1337-1344 (2008).
43. Wykes M, Pombo A, Jenkins C, MacPherson GG. Dendritic cells interact directly with naive B-lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 161, 1313-1319 (1998). (Pubitemid 28380559)
44. Le Roux D, Le Bon A, Dumas A et al. Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood 119, 95-105 (2011).
45. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 115, 216-225 (2006). (Pubitemid 44559708)
46. Gao W, Xiao Z, Radovic-Moreno A, Shi J, Langer R, Farokzad OC. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol. Biol. 629, 53-67 (2010).
47. Tezuka H, Ohteki T. Regulation of intestinal homeostasis by dendritic cells. Immunol. Rev. 234, 247-258 (2010).
48. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9, 679-691 (2009).
49. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol. Rev. 234, 120-141 (2010).
50. Kaplan DH. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol. 31, 446-451 (2010).
51. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 22, 124-130 (2010).
52. Dam TK, Brewer CF. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology 20, 270-279 (2009).
53. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum. Vaccines 7, 811-827 (2011).
54. Ueno H, Klechevsky E, Schmitt N et al. Targeting human dendritic cell subsets for improved vaccines. Semin. Immunol. 23, 21-27 (2011).
55. Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol. 33, 71-77 (2011).
56. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V. targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol. Cell Biol. 88, 424-430 (2010).
57. Stoitzner P, Green LK, Jung JY et al. Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J. Immunol. 180, 1991-1998 (2008).
58. Garcia-Gaumont C, Seksek O, Grzybowska J, Borowski E, Bolard J. delivery systems for antisense oligonucleotides. Pharmacol. Ther. 87, 255-277 (2000).
59. Mahato RI, Takakura Y, Hashida M. Development of targeted delivery systems for nucleic acid drugs. J. Drug Target. 4, 337-357 (1996).
60. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Exp. Opin. Drug Del. 8, 505-519 (2011).
61. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release 116, 255-264 (2006). (Pubitemid 44854274)
62. Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J. Control. Release 161, 600-608 (2012).
63. Li W, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24, 438-449 (2007). (Pubitemid 46295166)
64. Slütter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J. Control. Release 154, 123-130 (2011).
65. Hassane FS, Saleh AF, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67, 715-726 (2010).
66. Vazquez-Calvo A, Saiz J-C, McCullough KC, Sobrino F, Martin-Acebes MA. Acid-dependent viral entry. Virus Res. 167(2), 125-137 (2012).
67. Mueller J, Kretzschmar I, Volkmer R, Boisguerin P. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug. Chem. 19, 2363-2374 (2008).
68. Lundin P, Johansson H, Guterstam P et al. Distinct uptake routes of cell-penetratng peptide conjugates. Bioconjug. Chem. 19, 2535-2542 (2008).
69. Zaro JL, Shen W-C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun. 307, 241-247 (2003). (Pubitemid 36818860)
70. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 20 1775-1784 (2006). (Pubitemid 44933791)
71. Summerton JE. A novel reagent for safe, effective delivery of substances into cells. Ann. NY Acad. Sci. 1058, 62-75 (2005).
72. Boudier A, Aubert-Plouëssel A, Gérardin C et al. Tripartite siRNA micelles as controlled delivery systems for primary dendritic cells. Drug Dev. Ind. Pharm. 35, 950-958 (2009).
73. Diaz-Moscoso A, Vercauteren D, Rejman J et al. Insights in cellular uptake mechanisms of pDNA-polycationic amphiphilic cyclodextrin nanoparticles (CDplexes). J. Control. Release 143, 318-325 (2010).
74. Dierendonck M, De Koker S, Vervaet C, Remon JP, De Geest BG. Interaction between polymeric multilayer capsules and immune cells. J. Control. Release 161, 592-599 (2012).
75. Hu Y, Litwin T, Nagaraja AR et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7, 3056-3064 (2007). (Pubitemid 350132930)
76. Hu Y, Lu JJ, Atukorale PU et al. Cytosolic delivery mediated via electrostatic surface binding of protein, virus or siRNA cargoes to pH-responsive core-shell gel. Biomacromolecules 10, 756-765 (2009).
77. Howard KA. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug. Del. Rev. 61, 710-720 (2009).
78. Laga R, Carlisle R, Tangney M, Ulbrich K, Seymour LW. Polymer coatings for delivery of nucleic acid therapeutics. J. Control. Rel. 161, 537-553 (2012).
79. Sharma R, Ghasparian A, Robinson JA, McCullough KC. Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS ONE e43248 (2012).
80. Midoux P, Pichon C, Yaouanc J-J, Jaffrès P-A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol. 157, 166-178 (2009).
81. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J. Control. Release 151, 220-228 (2011).
82. Gonzalez-Rodriguez ML, Rabasco AM. Charged liposomes as carriers to enhance the permeation through the skin. Exp. Opin. Drug Del. 8, 857-871 (2011).
83. Jiang H-L, Kim TH, Kim Y-K, Park I-Y, Cho M-H, Cho CS. Efficient gene delivery using chitosan-polyethylenimine hybrid systems. Biomed. Mater. 3(2), 025013 (2008).
84. Won Y-W, Lim KS, Kim Y-H. Intracellular organelle-targeted non-viral gene delivery systems. J. Control. Release 152, 99-109 (2011).
85. Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolym. Peptide Sci. 94, 763-770 (2010).
86. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188-1196 (2001). (Pubitemid 32776393)
87. Tavernier G, Andries O, Demeester J, Sanders NN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J. Control. Release 150, 238-247 (2011).
88. Ceppi M, Ruggli N, Tache V, Gerber H, McCullough KC, Summerfield A. Double-stranded secondary structures on mRNA induce type 1 interferon (IFN a/b) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J. Gene Med. 7, 452-465 (2005). (Pubitemid 40553126)
89. Liu MA. Gene-based vaccines: recent developments. Curr. Opin. Mol. Therapy 12, 86-93 (2010).
90. Dow SW. Liposome-nucleic acid immunotherapeutics. Exp. Opin. Drug Del. 5, 11-24 (2008). (Pubitemid 351234107)
91. Basha G, Novobrantseva TI, Rosin N et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Am. Soc. Gene Cell Ther. 19, 2186-2200 (2011).
92. Tesz GJ, Aouadi M, Prot M et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436, 351-362 (2011).
93. Subramanya S, Kim S-S, Abraham S et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress Dengue Virus infection and associated proinflammatory cytokine production. J. Virol. 84, 2490-2501 (2010).
94. Akita H, Kogure K, Moriguchi R et al. nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J. Control. Release 143, 311-317 (2010).
95. Kong Y, Ruan L, Ma L, Cui Y, Wang JM, Le Y. RNA interference as a novel and powerful tool in immunopharmacological research. Int. Immunopharm. 7, 417-426 (2007).
96. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat. Rev. Gen. 12, 329-340 (2011).
97. Akinc A, Zumbuehl A, Goldberg M et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008). (Pubitemid 351668042)
98. Howard KA, Rahbek UL, Liu X et al. RNA interference in vitro and in vivo using a Chitosan siRNA nanoparticle system. Mol. Ther. 14, 476-484 (2006). (Pubitemid 44296092)
99. Rahbek UL, Howard KA, Oupicky D et al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. 10, 81-93 (2008).
100. Boudier A, Aubert-Plouëssel A, Mebarek N et al. Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. J. Control. Release 154, 156-163 (2011).
101. Mockey M, Bourseau E, Chandrashekhar V et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART 1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14, 802-814 (2007). (Pubitemid 47262757)
102. Kim H-K, Wei H, Kulkarni A, Pogranichniy RN, Thompson DH. Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT. Biomacromolecules 13, 636-644 (2012).
103. Perche F, Benvegnu T, Berchel M et al. Enhancement of dendritic cells transfection in vivo and of vaccintion against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445-453 (2011).
104. Su X, Fricke J, Kavanagh DG, Irvine DJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 8, 774-787 (2011).
105. Debus H, Baumhof P, Probst J, Kissel T. delivery of messenger RNA using poly (ethylene imine)-poly (ethylene glycol)-copolymer blends for polyplex formation: biophysical characterization and in vitro transfection properties. J. Control. Release 148, 334-343 (2010).
106. Rejman J, Tavernier G, Bavarsad N, Demeester J, De Smedt SC. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 147, 385-391 (2010).
107. Khromykh AA. Replicon-based vectors of positive strand RNA viruses. Curr. Opin. Mol. Therapy. 2, 555-569 (2000).
108. Mandl CW. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers. Viral Immunol. 17, 461-472 (2004). (Pubitemid 40054227)
109. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev. Med. Virol. 12, 279-296 (2002).
110. Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Exp. Rev. Mol. Med. 10, e33 (2008).
111. Racanelli V, Behrens SE, Aliberti J, Rehermann B. Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity 20, 47-58 (2004). (Pubitemid 38134293)
112. Frey CF, Bauhofer O, Ruggli N, Summerfield A, Hofmann MA, Tratschin JD. Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet. Res. 37, 655-670 (2006). (Pubitemid 44543951)
113. Suter R, Summerfield A, Thomann-Harwood LJ, McCullough KC, Tratschin JD, Ruggli N. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-alpha/beta and carry foreign genes. Vaccine 29, 1491-1503 (2011).
114. Suzuki R, Winkelmann ER, Mason PW. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol. 83, 1870-1880 (2009).
115. Kucharzik T, Lugering N, Rautenberg K et al. Role of M cells in intestinal barrier function. Ann. NY Acad. Sci. 915, 171-183 (2000). (Pubitemid 32059378)
116. Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 26, 6221-6224 (2008).
117. Martin-Latil S, Gnadig NF, Mallet A et al. Transcytosis of HTLV-1 across a tight human epithelial barrier and infection of sub-epithelial dendritic cells. Blood 120(3), 572-580 (2012).
118. Chieppa M, Rescigno M, Huang AY, Germain RN. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J. Exp. Med. 203, 2841-2852 (2006). (Pubitemid 46026162)
119. Lelouard H, Fallet M, de Bovis B, Meresse S, Gorvel JP. Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology 142, 592-601 e593 (2012).
120. Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361-367 (2001). (Pubitemid 33706348)
121. Vallon-Eberhard A, Landsman L, Yogev N, Verrier B, Jung S. Transepithelial pathogen uptake into the small intestinal lamina propria. J. Immunol. 176, 2465-2469 (2006). (Pubitemid 43201697)
122. Soloff AC, Barratt-Boyes SM. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res. 20, 872-885 (2010).